Stock TTNP TITAN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Titan Pharmaceuticals, Inc.

Equities

TTNP

US8883147055

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
7.32 USD +3.09% Intraday chart for Titan Pharmaceuticals, Inc. +0.82% -11.28%
Apr. 01 Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 26 Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Titan Pharmaceuticals : Non-Reliance on Previously Issued Financial Report - Form 8-K
PU
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Titan Pharmaceuticals : Private Placement - Form 8-K
PU
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule
MT
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
AQ
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024
CI
Reverse Split: 1 of 20
FA
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - December 28, 2023
AQ
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split
MT
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
AQ
Titan Pharmaceuticals: Q3 Earnings Snapshot
AQ
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Titan Pharmaceuticals, Inc. Announces Board Changes
CI
Titan Pharmaceuticals Appoints New Chairman of the Board
MT
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
AQ
Titan Pharmaceuticals, Inc. Announces Board Resignations
CI
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
AQ
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd
CI
TITAN PHARMACEUTICALS : UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION - Form 8-K
PU
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TTNP Stock
  4. News Titan Pharmaceuticals, Inc.